By Stephen Nakrosis
Shares of Clearmind Medicine Inc. were trading higher connected the Nasdaq connected Thursday, pursuing results from a survey of a psychedelic-derived obesity attraction successful rodents.
The biotech institution said animals treated with the company's cause candidate, MEAI, "showed accrued vigor expenditure, amended abdominous utilization and value nonaccomplishment of 20%, portion reducing their wide abdominous wide and preserving their thin assemblage mass."
At 2:19 p.m. ET, the company's shares were trading 8.9% higher, astatine $3.55 per share.
"We're precise excited astir these results, which suggest that MEAI whitethorn beryllium effectual successful treating obesity, 1 of the world's astir pressing problems," Dr. Adi Zuloff-Shani, the company's main executive, said.
Write to Stephen Nakrosis astatine stephen.nakrosis@wsj.com
English (US)